换一批
换一批The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
作者：
主题词
抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);女(雌)性(Female);卫生资源(Health Resources);人类(Humans);发病率(Incidence);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);蛋白激酶抑制剂(Protein Kinase Inhibitors);回顾性研究(Retrospective Studies);治疗结果(Treatment Outcome);美国(United States)
DOI
10.1016/j.lungcan.2019.07.021
PMID
31733614
发布时间
2020-09-01
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
